Daratumumab, an anti-CD38 monoclonal antibody, has revolutionized the treatment outcome and prognostic expectations in patients with relapsed myeloma. The USFDA approved it in November 2015 for treating patients with relapsed refractory multiple myeloma (RRMM) and those with newly diagnosed multiple myeloma (MM) who are ineligible for stem cell transplant.

Daratumumab, as the newest class of therapeutics for MM, has demonstrated substantial clinical efficacy and rapid and durable response in patients with RRMM who relapse after initial therapy or are refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) [1,2].